Cane Patricia A
Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i37-40. doi: 10.1093/jac/dkp258.
Several new antiretroviral drugs have recently been licensed for use in HIV-1-infected patients. These include drugs in two new classes: an integrase inhibitor (raltegravir) and a CCR5 co-receptor antagonist (maraviroc). In addition, two new protease inhibitors, atazanavir and darunavir, which have activity against viruses resistant to other protease inhibitors, have come into clinical use. Finally etravirine, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) is being increasingly used in patients whose virus is resistant to the earlier NNRTIs. These clinical advances have required the development of novel assays and interpretation systems for detection of resistance to allow the laboratory monitoring of patients receiving these new therapies.
最近，几种新型抗逆转录病毒药物已获许可用于治疗HIV-1感染患者。这些药物包括两类新药：一种整合酶抑制剂（雷特格韦）和一种CCR5共受体拮抗剂（马拉维罗）。此外，两种新型蛋白酶抑制剂阿扎那韦和达芦那韦已投入临床使用，它们对耐其他蛋白酶抑制剂的病毒具有活性。最后，依曲韦林是一种新型非核苷类逆转录酶抑制剂（NNRTI），越来越多地用于其病毒对早期NNRTI耐药的患者。这些临床进展需要开发新的检测方法和解读系统来检测耐药性，以便对接受这些新疗法的患者进行实验室监测。
